Business Wire

ActiveViam’s Atoti Powers SEB’s New P&L Sentinel for Streamlined Trading Desk Oversight

Share

ActiveViam, a global provider of advanced data analytics and decision-making solutions for the Financial Services industry, announced today that SEB AB, the leading Nordic corporate bank, has implemented and rolled out Atoti, ActiveViam's flagship product, as their P&L reporting solution.

Replacing a previous technology that was heavily based on spreadsheets and ad-hoc procedures, Atoti is now being used to investigate and report Actual P&L, create adjustments, and perform sign-off on aggregated P&L figures. The application called P&L Sentinel supports P&L Control and fifteen trading desks covering all traded assets of SEB.

Atoti's multidimensional cubes together with its distributed data architecture, allows SEB to have on-the-fly access from the top of house to the most granular trade details with access to historical data within forty business days, as well as aggregated historical data by portfolio supporting MTD, QTD, and YTD calculations.

Atoti Sign Off, a module in the Atoti product suite, has also been deployed to oversee and control the bank's daily internal approval and reporting operations satisfying the needs of internal stakeholders (P&L Control and Front Office).

All this is brought together under Atoti UI providing SEB with a unified and flexible set of dashboards. These support not only analytics and reporting but also the end-of-day approval process. These were configured so as to adhere to the firm's standards for workflow and approval.

SEB Head of Market Risk, Rasoul Najafi said: “We have successfully implemented P&L Sentinel within Atoti, modernizing our P&L management with a workflow-driven platform.

"This enables us to efficiently control and report daily trading P&L while providing enhanced drill-down capabilities. Both front office traders and risk controllers can seamlessly analyze figures at various levels. The solution brings improved oversight, transparency, and adaptability to our P&L processes.”

Shelly Magee, CEO of ActiveViam added, "We are delighted to expand our partnership with SEB with a long term commitment to support not only their liquidity but also their P&L reporting and operational workflow. This was a challenging, large-scale deployment of Atoti on the cloud and, together, we have built a world class application."

About SEB
SEB is one of the largest banks in Sweden, along with Svenska Handelsbanken and Swedbank. SEB is also the leading Nordic corporate bank. The bank was founded in 1856 and has a long history in the banking industry. In 1964, SEB released the Eurocard credit card, which was an alternative to American Express.

About ActiveViam
ActiveViam is a fast-growing financial data analytics solution provider.

Built for and trusted by leading financial institutions, ActiveViam delivers active intelligence for complex financial analytics.

It combines unrivaled technology, continuous innovation and exceptional people to unlock the power of real-time and granular data at scale.

Designed as a high-performance semantic layer, ActiveViam’s flagship product Atoti, allows clients to implement built-in front office and risk business solutions while accessing customizable technology.

ActiveViam is present in the world’s leading financial marketplaces: London, New York, Singapore, Sydney, Hong Kong, Paris and Frankfurt.

For more information, please visit: activeviam.com or follow on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520048578/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye